Provided by Tiger Trade Technology Pte. Ltd.

Longeveron Inc

0.8378
-0.0071-0.84%
Post-market: 0.7695-0.0683-8.15%17:08 EDT
Volume:771.80K
Turnover:628.21K
Market Cap:26.47M
PE:-0.84
High:0.8700
Open:0.8500
Low:0.8049
Close:0.8449
52wk High:1.23
52wk Low:0.4750
Shares:31.60M
Float Shares:27.26M
Volume Ratio:0.91
T/O Rate:2.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0000
EPS(LYR):-1.2917
ROE:-203.61%
ROA:-90.95%
PB:2.54
PE(LYR):-0.65

Loading ...

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

GlobeNewswire
·
Jun 09

Longeveron Announces CFO Transition to Internal Successor

TIPRANKS
·
Jun 06

BRIEF-Longeveron - On June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026 - SEC Filing

Reuters
·
Jun 06

Longeveron - on June 1, Lisa Locklear to Step Down as CFO Effective July 10, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 06

Longeveron - Anticipates Marie Washburn to Be Elevated to CFO Pending Final Contract - SEC Filing

THOMSON REUTERS
·
Jun 06

Longeveron to present at BIO International Convention 2026

Reuters
·
Jun 04

Longeveron shifts to capital-light model, targets licensing partners for laromestrocel

Reuters
·
May 21

Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

THOMSON REUTERS
·
May 21

Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate

Benzinga Earnings
·
May 14

Longeveron Q1 revenue rises, beats analyst estimates

Reuters
·
May 14

BRIEF-Longeveron Q1 EPS USD -0.19

Reuters
·
May 14

Longeveron Q1 Revenue USD 378 Thousand

THOMSON REUTERS
·
May 14

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

GlobeNewswire
·
May 14

Longeveron Q1 net loss narrows 6% to $4.74 million; revenue rises to $398,000

Reuters
·
May 14

Longeveron reports DMC approval for laromestrocel study to continue as designed

TIPRANKS
·
May 12

Longeveron Cut to Hold From Buy by Maxim Group

Dow Jones
·
May 12

Longeveron downgraded to Hold from Buy at Maxim

TIPRANKS
·
May 11

Longeveron DMC clears Phase 2b HLHS stem cell trial to complete

Reuters
·
May 11

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2B Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (Hlhs)

THOMSON REUTERS
·
May 11

Longeveron Inc - Top-Line Results From Elpis Ii Trial Anticipated in August 2026

THOMSON REUTERS
·
May 11